Vaderis Therapeutics Raises $152 Million Series B for Rare Disease Therapy

Vaderis Therapeutics has successfully closed a $152 million Series B financing round, with EQT Life Sciences being a significant investor, contributing $17.5 million. This capital infusion is critical for the company's efforts to develop the first approved therapy for hereditary hemorrhagic telangiectasia (HHT), a rare genetic vascular disease.

The financing will support the initiation of the global Phase 3 HEROIC study. This study will evaluate engasertib, a drug candidate representing a potential first-in-class treatment for HHT. The condition is characterized by severe nosebleeds, chronic anemia, and life-threatening vascular abnormalities, with no existing approved therapies.

EQT Life Sciences brings its experience in supporting biotechnology firms through late-stage clinical development to this investment. Vaderis Therapeutics aims to successfully navigate engasertib through clinical trials and bring the therapy to patients who currently lack treatment options.

The absence of approved treatments for HHT highlights the urgent need for novel therapeutic approaches. The advancement of engasertib through clinical development, now bolstered by this significant funding, holds the potential to substantially improve the quality of life and prognosis for individuals affected by this rare disorder.